Papers - MATSUURA Motoki

Fatty Acid Metabolism Regulators Have Pivotal Roles in the Pathogenesis of Ovarian Carcinoma

Megumi Watanabe, Motoki Matsuura, Tatsuya Sato, Makoto Usami, Tsuyoshi Saito, Masato Furuhashi, Kohichi Takada, Hiroshi Ohguro

International Journal of Molecular Sciences    2025.05

DOI

Risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancer patients with vaginal natural orifice transluminal endoscopic surgery (vNOTES)

Masato Tamate, Motoki Matsuura, Sachiko Nagao, Shoko Kurokawa, Taishi Akimoto, Tsuyoshi Saito

International Journal of Gynecological Cancer    2025.04

DOI

【エネルギーデバイス アラカルト-知っておきたい使い方の留意点と技術革新】総論 モードの特性と使い分け

玉手 雅人, 松浦 基樹, 齋藤 豪

臨床婦人科産科 ( (株)医学書院 )  78 ( 12 ) 1083 - 1090  2024.12

　View Summary

＜文献概要＞●電気メスのモードと本体の使い分け:電気メスの効果と性能は,モードと出力設定で変化するが,電気メスを接続する本体の種類によっても異なる.●他の手術機器との使い分け,バイポーラ・アドバンスドバイポーラ・バイクランプの使い分け:電気メス,バイポーラ,アドバンスドバイポーラ,超音波凝固切開装置の組み合わせは術式・手技・コストで考慮する.●機械の特性を理解して,術者が自身の技量や手術スタイルに合わせてエネルギーデバイスを扱うことが重要と思われる.

【エネルギーデバイス アラカルト-知っておきたい使い方の留意点と技術革新】各種デバイスの原理・有用性と使用上の注意点 シーリングデバイス

松浦 基樹, 玉手 雅人, 齋藤 豪

臨床婦人科産科 ( (株)医学書院 )  78 ( 12 ) 1104 - 1111  2024.12

　View Summary

＜文献概要＞●シーリングデバイスは直径7mmまでの血管や組織束がシール可能であり,超音波凝固切開装置より太い血管をシールすることができる.●シーリングデバイスは高周波エネルギーを瞬時に供給して血管のシールを行うため,手術効率が向上するだけではなく,熱の拡散を極力抑えることで周囲の組織への影響を最小限に抑えることができる.●外科医は各デバイスの原理や有用性・注意点などを習熟したうえで,これらのデバイスを使用するべきである.

Successful Outcome of Stage IB3 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Vaginal Radical Trachelectomy: A Case Report.

Masato Tamate, Motoki Matsuura, Masayuki Someya, Tasuku Mariya, Shinichi Ishioka, Tsuyoshi Saito

Cureus   16 ( 10 ) e71626  2024.10  [International journal]

　View Summary

Vaginal trachelectomy, which involves resecting the cervix and its parametrium, is a fertility-sparing option for the treatment of early-stage cervical cancer. Although no consensus has been reached on whether simple or radical trachelectomy is preferable, the vaginal approach is typically avoided for tumors larger than 2 cm due to concerns about recurrence. However, some evidence suggests that fertility preservation may still be viable for select patients with larger tumors. This case report describes a woman with bulky cervical cancer who wished to preserve her fertility. After undergoing neoadjuvant chemotherapy (NAC) and vaginal radical trachelectomy (VRT), she achieved a favorable oncological and perinatal outcome, successfully giving birth to a near-full-term baby. The report outlines the patient's management before, during, and after the procedure, including perinatal care. While careful selection of candidates is crucial, accumulating case reports and future trials are expected to shed more light on this treatment approach.

DOI PubMed

Human papillomavirus self‐sampling and urine‐sampling tests and the management and short‐term outcomes of cervical intraepithelial neoplasia: A prospective observational study

Motoki Matsuura, Masato Tamate, Sachiko Nagao, Taishi Akimoto, Fukiko Kasuga, Kimihito Saito, Satoshi Shikanai, Yoko Nishimura, Mizue Teramoto, Tsuyoshi Saito

Journal of Obstetrics and Gynaecology Research    2024.10

DOI

Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.

Daisuke Aoki, Tsutomu Tabata, Satoshi Yanagida, Toshiaki Nakamura, Eiji Kondo, Junzo Hamanishi, Kenichi Harano, Kosei Hasegawa, Takeshi Hirasawa, Kensuke Hori, Shinichi Komiyama, Motoki Matsuura, Hidekatsu Nakai, Hiroko Nakamura, Jun Sakata, Kazuhiro Takehara, Munetaka Takekuma, Yoshihito Yokoyama, Yoichi Kase, Shuuji Sumino, Junpei Soeda, Ai Kato, Ajit Suri, Aikou Okamoto, Toru Sugiyama

Journal of gynecologic oncology   35 ( 5 ) e114  2024.09  [International journal]

　View Summary

OBJECTIVE: To evaluate the long-term efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. METHODS: This was the follow-up analysis of a phase 2, multicenter, open-label, single-arm study in Japanese women with homologous recombination-deficient, platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who had completed 3-4 lines of chemotherapy and were poly(ADP-ribose) polymerase inhibitor naïve. Participants received niraparib (starting dose, 300 mg) once daily in continuous 28-day cycles until objective disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was confirmed objective response rate (ORR), as assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Safety evaluations included treatment-emergent adverse events (TEAEs). RESULTS: 20 patients were enrolled in the study and included in both efficacy and safety analyses. Median total study duration was 759.5 days. Median dose intensity was 201.3 mg/day. Confirmed ORR was 60.0% (90% confidence interval [CI]=39.4-78.3); 2 patients had complete response and 10 patients had partial response. Median duration of response was 9.9 months (95% CI=3.9-26.9) and the disease control rate was 90.0% (95% CI=68.3-98.8). The most common TEAEs were anemia (n=15), nausea (n=12), and decreased platelet count (n=11). TEAEs leading to study drug dose reduction, interruption, or discontinuation were reported in 16 (80.0%), 15 (75.0%), and 2 patients (10.0%), respectively. CONCLUSION: The long-term efficacy and safety profile of niraparib was consistent with previous findings in the equivalent population in non-Japanese patients. No new safety signals were identified. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03759600.

DOI PubMed

IB3期の子宮頸癌に対して術前化学療法後に広汎子宮頸部摘出術を施行し分娩となった1例

佐藤 冴子, 染谷 真行, 玉手 雅人, 松浦 基樹, 森下 美幸, 馬場 剛, 石岡 伸一, 齋藤 豪

北日本産科婦人科学会総会・学術講演会プログラム・抄録集 ( 東北連合産科婦人科学会・北日本産科婦人科学会 )  71回   48 - 48  2024.09

ロボット支援子宮全摘出術での発光式尿管カテーテルと子宮トランスイルミネーターの使用経験

幅田 周太朗, 黒川 晶子, 有元 千紘, 長尾 沙智子, 玉手 雅人, 秋元 太志, 松浦 基樹, 齋藤 豪

北日本産科婦人科学会総会・学術講演会プログラム・抄録集 ( 東北連合産科婦人科学会・北日本産科婦人科学会 )  71回   78 - 78  2024.09

当院における類内膜癌G3症例の細胞診・病理形態学的評価と臨床経過の検討

幅田 周太朗, 齋藤 晋平, 有元 千紘, 野藤 五沙, 長尾 沙智子, 黒川 晶子, 玉手 雅人, 真里谷 奨, 秋元 太志, 松浦 基樹, 岩崎 雅宏, 齋藤 豪

日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  66回   327 - 327  2024.07

Analysis of Treatment Response With Proteins Related to Tumor Immunity in Postoperative Irradiated Cervical Cancer Patients.

Shoh Mafune, Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Ryu Okuda, Masahiro Iwasaki, Motoki Matsuura, Terufumi Kubo, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito, Koh-Ichi Sakata

Anticancer research   44 ( 7 ) 3077 - 3086  2024.07  [International journal]

　View Summary

BACKGROUND/AIM: This study evaluated the association between programmed cell death-ligand 1 (PD-L1) and prognosis in patients with cervical cancer treated with postoperative radiation and the impact of neoadjuvant chemotherapy (NAC) on this association. PATIENTS AND METHODS: Immunohistochemical analysis was performed on biopsy specimens from 42 patients who did not receive NAC and from paired samples before (biopsies) and after (resected tissues) chemotherapy from 46 patients who received NAC to determine the association of PD-L1 with radiotherapy outcomes. RESULTS: In the non-NAC group, patients with ≥10% PD-L1-expressing tumor cells prior to treatment had better recurrence-free survival (RFS) than those with <10% PD-L1-expressing tumor cells (p=0.001). In the NAC group, RFS was significantly lower (p=0.005) in the group with a ≥5% reduction of PD-L1 expression in tumor cells after chemotherapy than in those with <5% reduction. In multivariate analysis, only PD-L1 expression (non-NAC group) and the change in PD-L1 expression (NAC group) were associated with RFS. CONCLUSION: Low PD-L1 expression in a cervical tumor prior to treatment was identified as a risk factor for a poor outcome after postoperative radiotherapy. Furthermore, NAC induces an immunological shift that reduces PD-L1 levels in tumor cells, thereby negatively impacting treatment outcomes.

DOI PubMed

当院における類内膜癌G3症例の細胞診・病理形態学的評価と臨床経過の検討

幅田 周太朗, 齋藤 晋平, 有元 千紘, 野藤 五沙, 長尾 沙智子, 黒川 晶子, 玉手 雅人, 真里谷 奨, 秋元 太志, 松浦 基樹, 岩崎 雅宏, 齋藤 豪

日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  66回   327 - 327  2024.07

当院における再発子宮体癌に対するPembrolizumab+Lenvatinibの使用経験

長尾 沙智子, 松浦 基樹, 黒川 晶子, 玉手 雅人, 秋元 太志, 幅田 周太朗, 岩崎 雅宏, 齋藤 豪

日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  66回   405 - 405  2024.07

The roles of tight junction protein cingulin in human endometrioid endometrial cancer.

Arisa Kura, Kimihito Saito, Takumi Konno, Takayuki Kohno, Hiroshi Shimada, Tadahi Okada, Soshi Nishida, Daichi Ishii, Motoki Matsuura, Tsuyoshi Saito, Takashi Kojima

Tissue barriers     2361976 - 2361976  2024.06  [International journal]

　View Summary

The bicellular tight junction molecule cingulin (CGN) binds to microtubules in centrosomes. Furthermore, CGN contributes to the tricellular tight junction (tTJ) proteins lipolysis-stimulated lipoprotein receptor (LSR) and tricellulin (TRIC). CGN as well as LSR decreased during the malignancy of endometrioid endometrial cancer (EEC). Although tTJ protein LSR is involved in the malignancy of some cancers, including EEC, the role of CGN is unknown. In this study, we investigated the roles of CGN with tTJ proteins in human EEC cells by using the CGN-overexpressing EEC cell line Sawano. In 2D cultures, CGN was colocalized with LSR and TRIC at tTJ or at γ-tubulin-positive centrosomes. In immunoprecipitation with CGN antibodies, CGN directly bound to LSR, TRIC, and β-tubulin. Knockdown of CGN by the siRNA decreased the epithelial barrier and enhanced cell proliferation, migration and invasion, as well as knockdown of LSR. In the Sawano cells cocultured with normal human endometrial stromal cells, knockdown of CGN decreased expression of LSR and TRIC via MAPK and AMPK pathways. In 2.5D cultures, knockdown of CGN induced the formation of abnormal cysts and increased the permeability of FD-4 to the lumen. In 2D and 2.5D cultures, treatment with β-estradiol with or without EGF or TGF-β decreased CGN expression and the epithelial permeability barrier and enhanced cell migration, and pretreatment with EW7197+AG1478, U0126 or an anti-IL-6 antibody prevented this. In conclusion, CGN, with tTJ proteins might suppress the malignancy of human EEC and its complex proteins are sensitive to estrogen and growth factors derived from stromal cells.

DOI PubMed

vNOTESの可能性を広げる術式の研究

玉手 雅人, 松浦 基樹, 長尾 沙智子, 黒川 晶子, 諸井 明仁, 秋元 太志, 齋藤 豪

産婦人科手術 ( (株)メジカルビュー社 )  ( 35 ) 143 - 143  2024.06

hinotoriを用いた婦人科ロボット支援手術

長尾 沙智子, 松浦 基樹, 黒川 晶子, 玉手 雅人, 秋元 太志, 諸井 明仁, 齋藤 豪

産婦人科手術 ( (株)メジカルビュー社 )  ( 35 ) 150 - 150  2024.06

日本におけるCSTの現状,産婦人科CSTにおける役割

玉手 雅人, 松浦 基樹, 長尾 沙智子, 黒川 晶子, 秋元 太志, 幅田 周太朗, 齋藤 豪

産婦人科手術 ( (株)メジカルビュー社 )  ( 35 ) 121 - 121  2024.06

日本におけるCSTの現状,産婦人科CSTにおける役割

玉手 雅人, 松浦 基樹, 長尾 沙智子, 黒川 晶子, 秋元 太志, 幅田 周太朗, 齋藤 豪

産婦人科手術 ( (株)メジカルビュー社 )  ( 35 ) 121 - 121  2024.06

vNOTESを導入する際の諸問題 vNOTES,船頭多くして船海に出るために

玉手 雅人, 松浦 基樹, 長尾 沙智子, 黒川 晶子, 諸井 明仁, 秋元 太志, 幅田 周太朗, 齋藤 豪

産婦人科手術 ( (株)メジカルビュー社 )  ( 35 ) 137 - 137  2024.06

vNOTESの可能性を広げる術式の研究

玉手 雅人, 松浦 基樹, 長尾 沙智子, 黒川 晶子, 諸井 明仁, 秋元 太志, 齋藤 豪

産婦人科手術 ( (株)メジカルビュー社 )  ( 35 ) 143 - 143  2024.06